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Abstract:  Psoriasis is a chronic infl ammatory disease that affects primarily the skin and joints, with a worldwide 
incidence of 2-3%. Fifty percent of patients are women, most still diagnosed during childbearing years. Current-
ly,the estimate is that up to 107 thousand deliveries are performed annually in women with psoriasis, a percent-
age of them in women with moderate to severe disease. Fetal risks in pregnant women with psoriasis derive both 
from maternal disease and the medications used to control the illness. The purpose of this review is to study the 
effect of the main drugs used in the treatment of psoriasis and psoriatic arthritis during pregnancy and lactation, 
with particular focus on disease-modifying anti-rheumatic biological drugs, biological therapies, immunobiolog-
ics or biologics.
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 INTRODUCTION
Pregnancy planning in women with infl amma-
tory diseases requires the adjustment of medications 
that are both able to maintain the disease stable and 
are also compatible with embryonic and fetal develop-
ment. Withdrawal of all drugs before conception can 
lead to worsening of symptoms, which are as detri-
mental to the pregnancy prognosis as the continuation 
of substances able to harm the child’s development.1
Psoriasis is a chronic disease with a worldwide 
prevalence of approximately 2-3%, representing close 
to 5% of all cutaneous diseases.2,3 Most studies did not 
observe differences between genders, so almost 50% 
of patients are women, many of childbearing age, 
since the average age of diagnosis is 28 years and near-
ly 75% of cases occur before the age of 40.2,4
The purpose of this article is to review the im-
pact of drugs used in the treatment of psoriasis and 
psoriatic arthritis during pregnancy and lactation.
CORRELATION BETWEEN PSORIASIS AND PREGNANCY
The estimate is that 65 to 107 thousand deliver-
ies occur annually in women with psoriasis, of which 
9 to 15,000 have moderate to severe disease.5,6 Preg-
nancy may infl uence the severity of psoriasis. Approx-
imately 55% of patients improve during pregnancy, 
21% remain stable and 23% evolve with worsening 
of clinical manifestations.7,8 Moreover, a worsening 
of symptoms in the postpartum period is observed in 
about 40-90% of patients. Psoriatic arthritis occurs in 
10-30% of patients with psoriasis. Pregnancy may act 
as a triggering factor for the articular disease and 30-
40% of women relate the onset of psoriatic arthritis to 
the postpartum period.2
Risks to the fetus are dependent on the maternal 
disease activity and the medications used to treat it.
The uncontrolled infl ammation and excess of 
cytokines inherent to the process of psoriasis can in-
fl uence the course of pregnancy, however, little is re-
ported about this topic.9 Psoriasis autoimmune infl am-
mation resultsfrom dysfunctional T-helper cells with 
concomitant amplifi cation of proinfl ammatory cyto-
kines, mainly TNF-α, IL-1 and IL-6.5 Cytokine excess 
causes endothelial dysfunction, resulting in systemic 
and placental vasculopathies through platelet aggre-
gation, intermittent vasospasm and activation of the 
coagulation system.5,9 Placental vasculopathy has been 
linked to intrauterine growth retardation and low 
birth weight.10 The stress associated with chronic and 
 An Bras Dermatol. 2015;90(3):367-75.
RevistaABD3Vol90ingles.indd   367 22/05/15   12:02
368 Kurizky PS, Ferreira CC, Nogueira LSC, Mota LMH
recurrent diseases tends to impact mental health, in-
creasing the risk of alcohol abuse, depression, weight 
gain and smoking.11 Psoriasis is also associated with 
high rates of comorbidities, such as diabetes melli-
tus, cardiovascular diseases, obesity and metabolic 
syndromethat may also lead to complications during 
pregnancy and increase the risk of malformations.5,12 
Studies show that pregnant women with psoriasis fre-
quently present overweight/obesity, depression and 
smoking habits in the fi rst trimester and are also less 
compliant with the intake of vitamins and prenatal 
supplements.5,11
ANTIPSORIATIC TREATMENTS DURING PREGNANCY
Studies evaluating the effects of antipsoriatic 
drugs on fetuses are still limited.5,13 One reason for this 
stems from the selective bias against studies in preg-
nant women for ethical reasons. Usually, available 
information regarding the use of these medications 
during pregnancy originates from case-control or ret-
rospective studies with women who inadvertently 
used them.5,12 However, without a control group of 
untreated pregnant patients, the risk of teratogenic 
effects cannot be properly estimated.12 Studies in an-
imals may be useful to identify which drugs may be 
teratogenic, but it is not always possible to generalize 
these fi ndings to human pregnancy. Eventually, uncer-
tainty leads to unnecessary interruption of pregnan-
cies or inadequate treatment of mother and fetus.12
It is also important to recognize the available 
information regarding fetal malformations, when con-
sidering and evaluating teratogenicity.12 About 2% of 
all pregnancies have major congenital defects detected 
prenatally or at birth.14 Furthermore, 3% of children will 
have a diagnosis of congenital malformation during the 
fi rst year of life.12 These rates may be higher depending 
on maternal age, family and past medical histories.12
Topical treatments
Topical treatment, with the exception of some 
medications, is the fi rst-line treatment of psoriasis in 
pregnant and lactating women.5,7,13,15
Emollients should be tried fi rst, because of their 
lack of adverse effects, followed by low to medium 
potency corticosteroids.7,15 High potency corticoste-
roids must be used, when necessary, rather in the sec-
ond and third trimesters since, though not consensus, 
some studies have shown an association of their use 
with low birth weight.15 Safety and absorption of top-
ical corticosteroids are related to several factors, such 
as formulation vehicle, quantity applied, occlusion 
and application site. A practical approach is to advise 
the patient not to apply excessive amounts over large 
areas, or on those under occlusion, to avoid excessive 
absorption and possible risk of low birth weight.13
While not approved for psoriasis, tacrolim-
us has been used to treat it on intertriginous areas.15 
There are no studies on the use of topical tacrolimus 
during pregnancy, although there are considerable 
data on its oral use. Systemically, it has been associat-
ed with prematurity and low birth weight, although 
most likely the topical exposure would have lower 
correlation with those. Although oral tacrolimus has a 
safety pattern similar to cyclosporine, there are fewer 
studies available.15 Usually, topical calcineurin inhib-
itors have lower absorption than topical corticoste-
roids.16 Repeated applications, usage on large areas, 
and chronic use, were not associated with systemic 
drug accumulation in most studies. Some reports on 
systemic absorption of topical tacrolimus are found in 
patients with orofacial Crohn’s disease, erosive lichen 
planus, pyoderma gangrenosum and lamellar ichthy-
osis. However, adverse events related to systemic ab-
sorption were not observed in either of these cases.15
Treatment with topical salicylic acid is contro-
versial. Data regarding the infl uence of this drug’s 
topical application during pregnancy is limited, and 
although some authors advocate its use in restricted 
areas,12 others contraindicate it, arguing that the ab-
sorption can be substantial.15 Some cases of salicylism 
have been reported with the use of topical salicylic 
acid in concentrations ranging from 1 to 40%. Clini-
cal presentations include abdominal pain, vomiting, 
lethargy, hallucinations, confusion, hypoglycemia, 
deafness, tinnitus, tachypnea, irritability, metabolic 
acidosis, coma and death.15
Risks of other topical agents, such as anthralin 
and calcipotriol on human studies are not known and 
thus most authors contraindicate these treatments.7,15 
Calcipotriol is a by-product of vitamin D3, often used 
in combination with topical corticosteroids in order to 
increase their effectiveness and minimize irritation.12 
Nevertheless, studies evidenced its systemic absorp-
tion in humans after application on psoriasis plaques 
and the development of vitamin D-induced toxicity 
after treatment with calcipotriol tends to increase the 
risk of teratogenicity.12
Although the number of cases is limited, coal 
tar has been associated with spontaneous abortions 
and congenital disorders, and was considered terato-
genic in animal studies. Hence, it is not recommend-
ed during pregnancy.7,15 The main topical treatments 
used in psoriasis and their effects in pregnancy are 
summarized in chart 1,12,15 according to available data 
collected from bibliographical references analyzed in 
preparation for this review. 
 Mild psoriasis, in general, can be adequately 
treated with topical drugs but systemic treatments 
may be required in moderate to severe psoriasis.
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UVB phototherapy 
UVB phototherapy is the second-line treat-
ment.5,7,15 Although data is limited, so far it was not 
associated with increased risk of fetal abnormalities 
or prematurity.13,15 In cases with extensive lesions, this 
seems to be the safest therapy, however overheating 
during treatment should be avoided, especially during 
the fi rst 28 days of gestation, due to the increased risk 
of neural tube defects.13,15
The safety of PUVA with systemic psoralens is 
poorly known; although mutagenic potential has been 
demonstrated in studies with rats, few cases of pre-
maturity and fetal abnormalities have been reported 
in pregnant women.5,15 Thus, this treatment is not rec-
ommended as an option for fi rst or second line during 
pregnancy.15
Chart 212,15 describes the effects of different mo-
dalities of phototherapy during pregnancy, according 
to data collected from bibliographical references ana-
lyzed in preparation for this review.
CHART 1: Effects of the main topical medications used in psoriasis during pregnancy
Medication Adverse events in pregnancy
Topical 
Anthralin No available data
Calcipotriol No available data
Corticoids  Intrauterine growth retardation 
reported
Coaltar  Trisomy 13, spontaneous mis-
carriages
Salicylic acid  Oral use causes maternal and 
fetal hemostasis disorders
  




Tacrolimus  Low birth weight, prematurity 
and hyperkalemia with system-
ic use
Tazarotene Few data in humans
Adverse events in animals
No available data
Increased incidence of skeletal ab-
normalities, and incomplete pu-
bic bones ossifi cation
Fetal growth retardation
Omphalocele and umbilical hernia
Fetal death, growth retardation, 
cleft palate, teratogenic
Stenosis of the ductus arterio-
suswith systemic treatment
Malformations, fetal growth re-
tardation, fetal death with sys-
temic treatment
Teratogenic effects and fetal death 
with systemic use
Conclusion
Contraindicated due to the 
lack of available data
Contraindicated due to the 
lack of available data
Safe, except when used in 
large amounts and extensive 
areas, when it can be associat-
ed with low birth weight
Contraindicated due to the 
lack of available data
Contraindicated
Probably safe for topical use, 
however without enough 
data
Contraindicated
Systemic drug therapy 
Third-line treatments of psoriasis in pregnant 
women include systemic medications such as cortico-
steroids and cyclosporine.15
Systemic corticosteroids
Systemic corticosteroids are not routinely used 
in the treatment of psoriasis, because even though 
they result in the rapid clearing of lesions, reactivation 
of symptoms is common, demandingprogressively 
higher doses of medication with consequent increase 
in the incidence of adverseevents.17 Withdrawal of sys-
temic corticosteroids is also generally accompanied by 
immediate disease relapse or rebound, characterized 
by diffuse eruptive lesions, affecting the face and the 
dorsal area of the hands.17 In addition, their use may 
precipitate the development of erythrodermic or gen-
eralized pustular psoriasis.18 They are indicated in the 
treatment of persistent erythrodermia unresponsive to 
other therapies, which may be causing metabolic com-
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plications and also to treat von Zumbusch’s fulminant 
generalized pustular psoriasis when other drugs are 
ineffective or contraindicated.17,19
The use of systemic corticosteroids during preg-
nancy is associated with low birth weight and intra-
uterine growth retardation.15 The association between 
corticosteroid exposure in the fi rst trimester and sig-
nifi cant increase in orofacial clefts is controversial. 
After the placenta is developed, all steroids are inac-
tivated by placental 11-β-hydroxylase, thus granting 
relative protection to the fetus.1 The prolonged use of 
corticoids increases the risk of prematurity, intrauter-
ine growth restriction and the frequency of maternal 
adverse events such as hypertension, diabetes mellitus 
and osteoporosis.1 However, they constitute one of the 
recommended treatments for impetigo herpetiformis, 
severe pustular psoriasis,which commonly occurs in 
the later stages of pregnancy, and may be used to treat 
psoriatic arthritis.1,15 In these cases, planning the post-
partum replacement is vital to avoid the often-fatal 
cutaneous rebound of the disease.
Cyclosporine A
The use of cyclosporine A in transplanted preg-
nant women showed no increased risk to the fetus and 
may be an option in psoriasis.5,20 Its use was associated 
with low birth weight and prematurity in infants born 
to transplanted women.20 Little information is found 
on its infl uence in pregnant women with psoriasis, 
nonetheless, do to the lack of teratogenic effects, most 
authors recommend its use in patients with severe 
psoriasis.5,13,15,20
Other systemic medications
Other systemic drugs commonly used in psoria-
sis, such as methotrexate and acitretin, are contraindi-
cated during pregnancy.21 Methotrexate is teratogenic 
and mutagenic. It should be discontinued at least 3 
months before conception. 15 For methotrexate doses 
higher than 10mg/week, studies show that the sen-
sitive period for malformations is between 6-8 weeks 
after conception.1 Its use can lead to abortions, microg-
nathia, delayed development, craniostenosis, low set 
ears, abnormalities of the extremities and intrauterine 
growth retardation.13 Systemic retinoids are teratogen-
ic and cause cardiac, craniofacial, thymic and central 
nervous system malformations.13,15
The main effects of systemic drugs used in pso-
riasis and psoriatic arthritis during pregnancy are 
shown in chart 3,1, 12, 15, 20, 21  according to data collected 
from bibliographical references analyzed in prepara-
tion for this review.
Immunobiological therapies 
The experience with biological drugs during 
pregnancy is still limited.13
Theoretically, it is suggested that TNF-α is im-
portant in embryonic and fetal development and its 
depletion in mice leads to an increase in fetal death and 
structural defects.22 All anti-TNF-α drugs are, at least to 
a certain extent, IgG1 or IgG1-like antibodiesthat bind to 
TNF-α molecules causing down-regulation of their in-
fl ammatory actions. Human placenta appears to be im-
permeable to almost all major classes of antibodies, ex-
cept IgG, which consists of four subclasses (IgG1-IgG4).22 
Most of IgG in the fetus is of maternal origin, with IgG1 
being the more effectively transported class.1 Fetal levels 
are low up to the second trimester and increasemarkedly 
from the beginning of the third trimester, until the fetal 
levels are higher than the maternal onesat term.1 There is 
variability in the specifi c active transport of each medica-
tion. For example, certolizumab has no Fc portion thus 
its active FcRn-mediated transplacental transport is not 
expected.22
Studies published between 2010 and 2012 con-
fi rmed earlier data, that the use of infl iximab and 
adalimumab during pregnancy does not increase the 
risk of congenital malformations.1,23
CHART 2: Phototherapy modalities and their effects during pregnancy
Medication Adverse events in pregnancy
Phototherapy 
Topical PUVA  No available data
Systemic PUVA   Increased risk of low birth 
weight after phototherapy with 
methoxsalen in the mother 
  Prematurity, fetal abnormalities
UVB  Case report with living birth 
without alterations
Adverse events in animals
No available data
Increased fetal death rates, 
growth retardation, enlargement 
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CHART 3: Systemic drugs used in psoriasis and psoriatic arthritis and their infl uence during pregnancy
Medication Adverse events in pregnancy
Systemic 
Acitretin  Classic retinoid embryopathy 
(craniofacial, cardiac, thymi-
cand central nervous system 
malformations)
Corticoids  Likely association with intrau-
terine growth retardation and 
low birth weight, increased risk 
of orofacial clefts 
Cyclosporine  Increased risk of prematurity 
andintrauterine growth retar-
dation, impairment in T, B and 
NK cells development in ex-
posed children from mothers 
with compromised health
Methotrexate  Dose-dependent CNS, cranio-
facial and limb growth abnor-
malities (when used between 6 
and 8 weeks of gestation)
Sulfasalazine  Absence of congenital malfor-
mations
Lefl unomide  Absence of congenital defects 
or recognizable pattern of mal-
formations
Azathioprine Prematurity
Adverse events in animals
Increased frequency of craniofa-
cial, limb and other types of mal-
formations
Fetal growth retardation, steno-
sis of ductus arteriosus, craniofa-
cial, cardiac, genital and skeletal 
anomalies, abdominal wall de-
fects, neural tube and CNS de-
fects, behavioral disorders 
Alterations of immunological 
functions, fetal growth retardatio-
nand death
Increased fetal death, dose-de-
pendent malformations of limbs, 




Absence of congenital defects or 
low birth weight
Conclusion
Contraindicated, high risk of 
malformations
Minimal risk of orofacial 
clefts; should be avoided dur-
ing the fi rst trimester
Risk of malformations, pre-
maturity, intrauterine growth 
retardationand impairment 
in T cells development is low 
and may be linked to the ma-
ternal subjacent disease. Use 
indicated in patients with se-
vere cases. 
Contraindicated during hu-
man pregnancy, high risk
Safe
Limited data contraindicate 
its use, but there is apparent-
ly low risk of teratogenicity in 
humans
Safe
Infl iximab and adalimumab are complete anti-
bodies containing an IgG1 Fc portion actively trans-
ported through the placenta, that reach high blood 
levels in newborns after exposure during the late sec-
ond and third trimesters.1 Since the half-life of immu-
noglobulins is longer than several months in the new-
born child, there is an increased risk of infection. BCG 
vaccination with the live attenuated form of Mycobac-
terium bovis administered at 3 months resulted in fatal 
disseminated infection in a child of 4.5 months, whose 
mother had received infl iximab for Crohn’s disease 
during pregnancy. 24 This case led to the recommenda-
tion that vaccines with live agents should be avoided 
during the fi rst months of life in children exposed to 
anti-TNF-α medications during pregnancy.22
Several case reports did not detect maternal ad-
verse events or fetal anomalies after the use of adalim-
umab during pregnancy.15,23 Larger series are available 
on the use of infl iximab. The largest published study 
is a retrospective analysis of 96 pregnancies; the rates 
of adverse events were similar to those of the general 
population and a case of tetralogy of Fallot and an-
other of intestinal malrotation were reported.22 In a 
systematic review of the literature in 2011,Bogas& Le-
andro identifi ed reports of 156 pregnancies exposed to 
infl iximab and 106 to adalimumab, 70% and 90% of 
whichrespectively had been exposed during the fi rst 
trimester.25 Congenital malformations were identifi ed 
in 8 pregnancies treated with infl iximab and 8 with 
adalimumab. The abnormalities usually occurred in 
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isolated cases.25 Despite favorable results, the routine 
use of these drugs in pregnancy is still questioned.7
Etanercept and certolizumab differ from other 
TNF-α inhibitors: etanercept is a fusion protein con-
taining IgG1 Fc portion that presents less transpla-
cental transport than other monoclonal antibodies. Its 
concentration in the umbilical cord is about 4-7% of the 
concentration detected in the maternal blood.1 Certoli-
zumab pegol is a humanized anti-TNF antibody Fab 
fragment with high affi nity to TNF,conjugated with 2 
polyethylene glycol molecules. Therefore, it lacks the 
IgG Fc portion and there seems to be minimal trans-
placental transport, resulting in an average concen-
tration in the umbilical cord of 3.9% of the maternal 
concentration, while with infl iximab this rate is 160%.1
A study from the U.S. Organization of Teratol-
ogy Information Specialist (OTIS) Research Group 
was performed with 17 pregnant women exposed to 
etanercept that resulted in live births, including twins. 
One of the twins had stomach malrotation, one child 
had unilateral inguinal hernia and another presented 
congenital hypothyroidism, however the mother had 
Hashimoto’s thyroiditis. The authors concluded that 
there was no consistent pattern of abnormalities.26
Most case reports on etanercept conclude that 
there are no malformation or prematurity patterns. 
The only exception was one case with vertebral anom-
alies, anal atresia, cardiac disorders, tracheoesopha-
geal fi stula, esophageal atresia, kidney malformation 
and limb anomalies (formerly known as VATER syn-
drome) reported in 2006.27 This report was important, 
because based on animal models, there was a plausi-
ble connection between TNF-α inhibition and this syn-
drome. Subsequent revisions of cases submitted to the 
FDA by the same author, led to additional concerns 
about malformations in newborns whose mothers 
were treated with etanercept or infl iximab. Analysis of 
these cases showed that the alterations did not match 
VATER syndrome, rendering this case isolated and 
diffi cult to be interpreted as secondary to the use of 
that medication.15
Certolizumab is a Fab (antibody fragment that 
binds to the antigen fragment) without the Fc por-
tion, directed against TNF-α. Although not approved 
for psoriasis by the FDA, it has shown similar results 
to other TNF-α inhibitors in phase II studies in this 
disease.28 Since IgG is the only antibody that can be 
transferred from mother to fetus through the placen-
ta barrier through a specifi c Fc portion receptor, this 
medication would result in lower fetal exposure. Al-
though preliminary data seems positive, potential 
risks are still unknown.15
The OTIS group is conducting a cohort study 
with women, in the U.S. and Canada, which were 
exposed to immunomodulatory agents (including 
etanercept, adalimumab and certolizumab), compar-
ing them to women with the same autoimmune dis-
eases without exposure to biologic drugs and also to 
a healthy control group. Preliminary data analysis did 
not identifi ed, until now, any pattern of defects and 
none of the patients met the criteria for association 
with VACTER.22
The British Registry documented 130 pregnan-
cies in 118 women, classifying them into 3 groups: 1) 
women exposed to anti-TNF-α drugs at conception; 
2) women exposed to anti-TNF-α drugsin the past; 3) 
control group. The rate of miscarriage was higher in 
group 1 compared to group 2 (24% and 17%, respec-
tively).29
Based on the theory of low transplacental trans-
port of these molecules in the fi rst trimester, many ex-
perts advise discontinuation of treatment at concep-
tion or when pregnancy is confi rmed.1,7 However, for 
those patients whose symptoms tend to worsen during 
pregnancy or whose treatment discontinuation is not 
advisable, some authors advocate the maintenance of 
treatment during gestation.13,22 Nevertheless, given 
the increased placental transfer demonstrated during 
late pregnancy (at least for infl iximab, etanercept and 
adalimumab) and suggestions of impaired immuni-
ty, many favorthe discontinuation of treatment in the 
third trimester.1,22
Ustekinumab is a monoclonal antibody that 
binds to the p40 subunit, common to IL-12 and IL-23, 
thus inhibiting the action of these cytokines.30 Most of 
the available studies on ustekinumab were performed 
only in animals, so that most of the authors do not rec-
ommended its use during pregnancy.15 Although there 
are few reports published in the literature up to June 
2010, 42 unpublished cases of drug exposure during 
pregnancy were identifi ed.31 In all pregnant women, 
the drug was discontinued in order to limit fetal expo-
sure, since the transport of ustekinumab, a large IgG 
molecule, is modest until the late second and early 
third trimesters. Ten of these pregnancies resulted in 
live birthswithout abnormalities or adverse events, 
six resulted in spontaneous miscarriages, eight were 
electively discontinued, 2 were born alive, but with 
abnormalities and of the last 16 there was no informa-
tion available.31 Andrulonis et al reported the case of 
a patient with erythrodermic psoriasis and psoriatic 
arthritis, which  used the drug in the fi rst six weeks of 
pregnancy and later in the 26th and 37th weeks, with 
improvement of the cutaneous and articular symp-
toms. The delivery was uneventful. Even so, breast-
feeding was contraindicated due to evidence of drug 
passage through breast milk.30
Chart 4 details the main effects reported on im-
munobiological drugs during pregnancy.1, 9, 12, 15, 22, 26, 30, 31
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CONSIDERATIONS ON PSORIATIC ARTHRITIS 
Cases of psoriatic arthritis associated with preg-
nancy are rare. As a rule, drugs and dosages are re-
duced.32 Among the modifying antirheumatic drugs, 
sulfasalazine and cyclosporine are favored.32 One 
study with 74 pregnant women exposed to sulfasal-
azine did not demonstrate increase in congenital mal-
formations, confi rming previous studies.1,33
Methotrexate and cyclophosphamide inhibit 
cell division and are teratogenic to animals and hu-
mans, so, they are strictly contraindicated.32,34
Psoriatic arthritis can be treated with steroids during 
pregnancy, especially prednisolone or prednisone.32
Lefl unomide and azathioprine are occasionally 
used to treat psoriatic arthritis, with potential use in 
selected cases.
CHART 4: Biological drugs used in psoriasis and psoriatic arthritis and their infl uence during pregnancy
Medication Adverse events in pregnancy
Biological 
Adalimumab  Isolated cases of trisomy 18, 
megacolon, ventricular sep-
tal defects, hemangioma, 
Wolfe-Parkinson-White syn-
drome, neurofi bromatosis, 
VACTER syndrome, non-de-
scended testicle, microcephaly, 
congenital hip dysplasia, hy-
dronephrosis.
Alefacept No available data
Etanercept  Isolated cases of VATER syn-
drome and trisomy 18 and 21, 
pyloric stenosis, hip dysplasia, 
heart hypoplasia, inguinal her-
nia, congenital megacolon, ven-
tricular septal defects, trans-
verse stomach, hypospadias, 
congenital hypothyroidism
Infl iximab  Isolated cases of congenital mal-
formations (tetralogy of Fallot, 
intestinal malrotation, ventricu-
lar septal defects, anencephaly, 
polydactyly, kidney agenesis), 
intracerebral and intrapulmo-
nary bleeding, respiratory fail-
ure, developmental delay, death 
from unknown causes 
  Disseminated fatal infection af-
ter BCG vaccination 
Ustekinumab Miscarriages
Certolizumab  Absence of congenital malfor-
mations
Adverse events in animals
Fetal death and structural defects
No available data
Fetal death and structural defects
Fetal death and structural defects
Absence of adverse events re-
garding mortality, mental, mor-
phological and immunological 
development 
One study demonstrated viriliz-
ing effect in female monkeys
No available data
Conclusion
Limited data available, if ad-
ministration is justifi ed by the 
severity of maternal illness, 
discontinue it until 30th week
Contraindicated due to the 
lack of available data
Limited data available, if ad-
ministration is justifi ed by the 
severity of maternal illness, 
discontinue it until 30th week
Limited data available, if ad-
ministration is justifi ed by the 
severity of maternal illness, 
discontinue it until 30th week
Contraindicated due to limit-
ed available data 
Not yet approved for use in 
psoriasis
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Lefl unomide is a pyrimidine synthesis inhib-
itor, which is teratogenic in rats, rabbits, and mice, 
and thus contraindicated during human pregnancy. 
Studies comparing the pregnancy of 64 patients with 
rheumatoid arthritis exposed to lefl unomide in the 
fi rst trimester and 108 unexposed subjects did not 
demonstrate increase in birth defects or recognizable 
patterns of malformation.1 This result was confi rmed 
by a second study with 45 pregnancies exposed to le-
fl unomide 2 years prior even to the fi rst trimester.34 
These data indicate that lefl unomide is not a powerful 
human teratogen, although due to the limited number 
of pregnancies evaluated, the use of contraceptives is 
still recommended during its use and washout indi-
cated in cases of unplanned pregnancies.1,34
Azathioprine can lead to premature births, al-
though it was not associated to birth defects or low 
birth weight, confi rming the possibility of its use in 
pregnancy when indicated.1
ANTIPSORIATIC TREATMENTS DURING LACTATION
Regarding lactating women, there is a lack of 
information about medication safety during the breast-
feeding period. The fi rst line of treatment for breast-
feeding mothers is limited to emollients and low to 
medium potency corticosteroids.7 There are no known 
risks associated with emollients. Studies on topical ste-
roids during lactation are negligible, however these 
drugs should be considered before systemic ones (for 
small areas) when psoriasis treatment is necessary.15 
Creams should be applied after breastfeeding and re-
moved before the next session.7
No studies were found about UVB therapy in 
lactating women, but it seems to be safe and is indicat-
ed as a second-line treatment in these patients.7,15
Systemic corticosteroids may be used if nec-
essary, since minimal concentrations are detected in 
breast milk. Because cortisol half-life varies between 
2.5 and 3.5 hours, the authors recommend an interval 
of 4 hours between the intake of systemic corticoste-
roids and breastfeeding.15
Systemic medication levels can be measured in 
breast milk. The signifi cance of these dosages is uncer-
tain due to limited reports. Thus, methotrexate, acitre-
tin, cyclosporine, and psoralen (PUVA) are contraindi-
cated during breastfeeding.15,21
Data on the use of biological drugs are still 
sparse. The absorption of maternal antibodies through 
breast milk in humans is limited, with IgA as the pre-
dominant immunoglobulin isotype providing immuni-
ty to infants’ intestinal mucosa.35 Small amounts of IgG 
and other larger immunoglobulins cross the breast acini 
and thus cannot be found, in signifi cant quantities, in 
the blood of infants. For this reason, the passage of an-
ti-TNF drugs through breast milk is expected to be min-
imal. There are few data from experimental (animal) or 
clinical studiesto support this information.
Regarding etanercept, the case of a woman 
with ankylosing spondylitis, who used the medication 
throughout pregnancy and lactation, was described. 
Drug concentration was determined in maternal 
blood, cord blood, breast milk and the infant’s blood. 
Maternal-to-cord blood concentration ratio was 14:1, 
which shows low transplacental passage. Concentra-
tion in the breast milk was 5 ng/ml - a very low value, 
and etanercept was not detected in the infant’s blood.36 
It is believed that, because it is a large protein, the oral 
absorption of etanercept is minimal or null.37
In regard to infl iximab, the case of a woman with 
infl ammatory bowel disease, who used high doses of 
infl iximab (10mg/kg 4 in 4 weeks) during pregnancy 
and lactation due to a lack of response to conventional 
doses, has been described. Breast milk was collected 
and analyzed: infl iximab was not detected. The preg-
nancy went uneventfully and the child did not show 
any physical or developmental abnormalities.37
There are no consistent data on the passage of 
other biological drugs through breast milk. 
The use of biological drugs during lactation is 
controversial. Bae et al claim that, despite limited data 
and according to reported evidence, the levels of med-
ications in the breast milk of lactating women treated 
with etanercept or infl iximab have been described as 
smaller than those used in the treatment, so it appears 
that no signifi cant absorption occurs in infants.15 Never-
theless, also in view of limited data, Wheatherhead et al 
contraindicate its use.7
CONCLUSIONS
Topical treatments are the fi rst line treatment of 
psoriasis in pregnant and lactating women. In moder-
ate to severe cases, UVB phototherapy is the second line 
of treatment and the third line features systemic drugs.
Information found in the literature on the use 
of biological drugs during pregnancy and lactation is 
scarce, and as directed by the prescribing information 
packets, the use of these drugs should be avoided during 
pre-conception, pregnancy and lactation periods. 
However, with respect to anti-TNF-α, based on 
the evidence described and inferring on the currently 
existing guidelines on its use in patients with infl am-
matory bowel disease, it would be possible to adopt 
the following recommendations:38
Pre-conception exposure: since anti-TNF-α hy-
pothetically does not cross the placental barrier in the 
fi rst trimester, it would be possible to allow its use un-
til the moment of conception.
Exposure during pregnancy: anti-TNF-α drugs 
should be suspended during pregnancy. In case of very 
severe disease activity and after discussing it with the 
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patient, it is possible to contemplate the eventual pre-
scription or reintroduction of the drug, preferably, if 
feasible, with reduced doses, larger periods between 
applications, and treatment suspension between 8 to 
10 weeks before the expected date of delivery. 
Exposure during lactation: anti-TNF-α drugs 
should be avoided during lactation. However, in case 
of intense disease activity, prescribing such drugs 
would be possible if the benefi t to the mother out-
weighed the risk to the child.
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